Editas Medicine Newsroom

RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8

Futu NewsSep 19 19:31

Editas Medicine (EDIT) Receives a Hold From RBC Capital

TipRanksSep 19 18:47

Jones Trading Initiates Coverage On Editas Medicine With Buy Rating, Announces Price Target of $13

BenzingaSep 18 04:44

JonesTrading Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $13

Futu NewsSep 18 04:32

Editas Medicine Hold Rating With Revised Price Target Amidst Mixed Financial Signals

TipRanksAug 9 20:34

Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline

TipRanksAug 9 19:09

Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $7

BenzingaAug 9 02:45

Barclays Remains a Hold on Editas Medicine (EDIT)

TipRanksAug 8 20:11

Buy Rating on Editas Medicine as R&D Progress Signals Market Potential for Sickle Cell and Thalassemia Treatments

TipRanksAug 8 19:48

Editas Medicine Price Target Raised to $15.00/Share From $13.00 by B of A Securities

Dow JonesAug 8 19:30

Buy Rating Reaffirmed for Editas Medicine Amidst Promising Clinical Advancements and Future Prospects

TipRanksAug 8 19:27

Editas Medicine Analyst Ratings

BenzingaAug 8 19:23

Truist Securities Adjusts Price Target on Editas Medicine to $12 From $20, Maintains Buy Rating

MT NewswiresAug 8 18:18

TD Cowen Sticks to Their Buy Rating for Editas Medicine (EDIT)

TipRanksAug 8 00:17

RBC Cuts Price Target on Editas Medicine to $8 From $11, Keeps Sector Perform, Speculative Risk

MT NewswiresJul 9 19:55

Editas Medicine Analyst Ratings

BenzingaJun 19 00:47

Oppenheimer Maintains Perform on Editas Medicine, Maintains $12 Price Target

BenzingaJun 19 00:46

Editas Medicine Analyst Ratings

BenzingaMay 30 23:15

Editas Medicine Inc: Evercore ISI cuts target price from $15 to $7

Zhitong FinanceMay 30 21:18

Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential

TipRanksMay 10 13:45